Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs

Bone

Volumn 40, Issue 3, 2007, Pages 645-655

  Gluer C C ^a   Scholz Ahrens, K E ^b   Helfenstein, A ^a   Delling, G ^c   Timm, W ^d   Acil Y ^a   Barkmann, R ^a   Hassenpflug, J ^a   Stampa, B ^d   Bauss, F ^e   Schrezenmeir, J ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Synarc Inc   (Germany)

^e ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Bisphosphonate; Bone densitometry; Bone strength; Glucocorticoid; Minipig

Indexed keywords

ALKALINE PHOSPHATASE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; IBANDRONIC ACID; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE DISEASE; BONE MINERAL; BONE STRENGTH; BONE STRESS; CHEMICAL ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; LUMBAR SPINE; LUMBAR VERTEBRA; MINIPIG; MORPHOMETRICS; MULTIPLE CYCLE TREATMENT; NONHUMAN; QUANTITATIVE ANALYSIS; TREATMENT DURATION; URINALYSIS; VERTEBRA; YOUNG MODULUS;

ALKALINE PHOSPHATASE; ANIMALS; BIOMECHANICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; LUMBAR VERTEBRAE; OSTEOPOROSIS; SWINE; SWINE, MINIATURE;

EID: 33846828468     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.10.019     Document Type: Article

References (72)

1. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 44 (2001) 1496-1503
2. Açil Y., and Müller P.K. Rapid method for the isolation of the mature collagen cross-links, hydroxylysylpyridinoline and lysylpyridinoline. J. Chromatogr., A 664 (1994) 183-188
3. Adachi J.D., Bensen W.G., Brown J., Hanley D., Hodsman A., Josse R., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337 (1997) 382-387
4. Adachi J.D., Saag K.G., Delmas P.D., Liberman U.A., Emkey R.D., Seeman E., et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44 (2001) 202-211
5. Amin S., Lavalley M.P., Simms R.W., and Felson D.T. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J. Bone Miner. Res. 17 (2002) 1512-1526
6. Angeli A., Guglielmi G., Dovio A., Capelli G., de Feo D., Giannini S., et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39 (2006) 253-259
7. Augat P., Schorlemmer S., Gohl C., Iwabu S., Ignatius A., and Claes L. Glucocorticoid-treated sheep as a model for osteopenic trabecular bone in biomaterials research. J. Biomed. Mater. Res., A 66 (2003) 457-462
8. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92 (1993) 2577-2586
9. Banse X., Devogelaer J.P., Munting E., Delloye C., Cornu O., and Grynpas M. Inhomogeneity of human vertebral cancellous bone: systematic density and structure patterns inside the vertebral body. Bone 28 (2001) 563-571
10. Bauss F., Lalla S., Endele R., and Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol. 29 (2002) 2200-2208
11. Bauss F., Wagner M., and Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J. Rheumatol. 29 (2002) 990-998
12. Bell N.H., Bilezikian J.P., Bone III H.G., Kaur A., Maragoto A., and Santora A.C. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J. Clin. Endocrinol. Metab. 87 (2002) 2792-2797
13. Binkley N., Kimmel D., Bruner J., Haffa A., Davidowitz B., Meng C., et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J. Bone Miner. Res. 13 (1998) 1775-1782
14. Borah B., Dufresne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J. Bone Miner. Res. 17 (2002) 1139-1147
15. Borchers R.E., Gibson L.J., Burchardt H., and Hayes W.C. Effects of selected thermal variables on the mechanical properties of trabecular bone. Biomaterials 16 (1995) 545-551
16. Canalis E., Bilezikian J.P., Angeli A., and Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 34 (2004) 593-598
17. Chavassieux P., Buffet A., Vergnaud P., Garnero P., and Meunier P.J. Short-term effects of corticosteroids on trabecular bone remodeling in old ewes. Bone 20 (1997) 451-455
18. Chavassieux P., Pastoureau P., Chapuy M.C., Delmas P.D., and Meunier P.J. Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos. Int. 3 (1993) 97-102
19. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. Curr. Rheumatol. Rep. 6 (2004) 66-69
20. Dalle Carbonare L., Arlot M.E., Chavassieux P.M., Roux J.P., Portero N.R., and Meunier P.J. Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J. Bone Miner. Res. 16 (2001) 97-103
21. Dalle Carbonare L., Bertoldo F., Valenti M.T., Zenari S., Zanatta M., Sella S., et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 36 (2005) 645-652
22. Deloffre P., Hans D., Rumelhart C., Mitton D., Tsouderos Y., and Meunier P.J. Comparison between bone density and bone strength in glucocorticoid-treated aged ewes. Bone 17 (1995) 409S-414S
23. Eastell R., Devogelaer J.P., Peel N.F., Chines A.A., Bax D.E., Sacco-Gibson N., et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos. Int. 11 (2000) 331-337
24. Fritz P.C., Ward W.E., Atkinson S.A., and Tenenbaum H.C. Tamoxifen attenuates the effects of exogenous glucocorticoid on bone formation and growth in piglets. Endocrinology 139 (1998) 3399-3403
25. Glüer C.C., Blake G., Lu Y., Blunt B.A., Jergas M., and Genant H.K. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos. Int. 5 (1995) 262-270
26. Glüer C.C., Scholz-Ahrens K.E., Timm W., Barkmann R., Delling G., Bauss F., et al. The minipig is a good model for glucocorticoid-induced bone loss and shows efficacy of ibandronate treatment for this disorder. J. Bone Miner. Res. 17 Suppl. 1 (2002) S371
27. Grubbs F.E. Procedures for detecting outlying observations in samples. Technometrics 11 (1969) 1-21
28. Hahn M., Vogel M., and Delling G. Undecalcified preparation of bone tissue: report of technical experience and development of new methods. Virchows Arch., A, Pathol. Anat. Histopathol. 418 (1991) 1-7
29. Hordon L.D., Raisi M., Aaron J.E., Paxton S.K., Beneton M., and Kanis J.A. Trabecular architecture in women and men of similar bone mass with and without vertebral fracture: I. Two-dimensional histology. Bone 27 (2000) 271-276
30. Ikeda S., Morishita Y., Tsutsumi H., Ito M., Shiraishi A., Arita S., et al. Reductions in bone turnover, mineral, and structure associated with mechanical properties of lumbar vertebra and femur in glucocorticoid-treated growing minipigs. Bone 33 (2003) 779-787
31. Juraschek M., Seibel M.J., Woitge H.W., Krempien B., and Bauss F. Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis. Bone 26 (2000) 475-483
32. Kalender W.A., Felsenberg D., Louis O., Lopez P., Klotz E., Osteaux M., et al. Reference values for trabecular and cortical vertebral bone density in single and dual-energy quantitative computed tomography. Eur. J. Radiol. 9 (1989) 75-80
33. Kalender W.A., Klotz E., and Süss C. Vertebral bone mineral analysis: an integrated approach. Radiology 164 (1987) 419-423
34. King C.S., Weir E.C., Gundberg C.W., Fox J., and Insogna K.L. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif. Tissue Int. 59 (1996) 184-191
35. Lill C.A., Fluegel A.K., and Schneider E. Effect of ovariectomy, malnutrition and glucocorticoid application on bone properties in sheep: a pilot study. Osteoporos. Int. 13 (2002) 480-486
36. Lill C.A., Gerlach U.V., Eckhardt C., Goldhahn J., and Schneider E. Bone changes due to glucocorticoid application in an ovariectomized animal model for fracture treatment in osteoporosis. Osteoporos. Int. 13 (2002) 407-414
37. Linde F., Hvid I., and Madsen F. The effect of specimen geometry on the mechanical behaviour of trabecular bone specimens. J. Biomech. 25 (1992) 359-368
38. LoCascio V., Bonucci E., Imbimbo B., Ballanti P., Adami S., Milani S., et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 8 (1990) 39-51
39. Lyles K.W., Jackson T.W., Nesbitt T., and Quarles L.D. Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles. Am. J. Physiol. 264 (1993) E938-E942
40. Mittermayer V., Müller V.E., Albert J., Allolio B., Blind E., Böhning W., et al. DVO-Leitlinie Glukokortikoidinduzierte Osteoporose. Osteologie 12 (2004) 119-137
41. Monier-Faugere M.C., Friedler R.M., Bauss F., and Malluche H.H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J. Bone Miner. Res. 8 (1993) 1345-1355
42. Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., Bauss F., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J. Bone Miner. Res. 14 (1999) 1768-1778
43. Mosekilde L., Weisbrode S.E., Safron J.A., Stills H.F., Jankowsky M.L., Ebert D.C., et al. Evaluation of the skeletal effects of combined mild dietary calcium restriction and ovariectomy in Sinclair S-1 minipigs: a pilot study. J. Bone Miner. Res. 8 (1993) 1311-1321
44. Norrdin R.W., Histand M.B., Sheahan H.J., and Carpenter T.R. Effects of corticosteroids on mechanical strength of intervertebral joints and vertebrae in dogs. Clin. Orthop. (1990) 268-276
45. O'Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., Stewart S.A., et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145 (2004) 1835-1841
46. Reid D.M., Hughes R.A., Laan R.F., Sacco-Gibson N.A., Wenderoth D.H., Adami S., et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15 (2000) 1006-1013
47. Reid I.R. Pathogenesis and treatment of steroid osteoporosis. Clin. Endocrinol. (Oxf.) 30 (1989) 83-103
48. Reid I.R. Steroid-induced osteoporosis. Osteoporos. Int. 7 (1997) S213-S216
49. Ringe J.D., Dorst A., Faber H., Ibach K., and Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14 (2003) 801-807
50. Saag K.G., Emkey R., Schnitzer T.J., Brown J.P., Hawkins F., Goemaere S., et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339 (1998) 292-299
51. Sambrook P.N., Hughes D.R., Nelson A.E., Robinson B.G., and Mason R.S. Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann. Rheum. Dis. 62 (2003) 1215-1217
52. Scholz-Ahrens K.E., Barth C.A., Drescher K., Goralczyk R., Rambeck W.A., Wehr U., and Schrezenmeir J. Modulation of bone markers by dietary calcium in ovariectomized minipigs. Osteoporos. Int. 6 Suppl. 1 (1996) S141
53. Scholz-Ahrens KE, Barth CA, Kann P, Lüttges J, Roberts H, Schrezenmeir J. Impact of dietary calcium on the effect of ovariectomy on bone density in minipigs. 8: Suppl. 3, 101 (1998b). Osteoporos. Int. 8 (Suppl. 3), pp. 101; 1998.
54. Scholz-Ahrens K.E., Barth C.A., Kann P., Lüttges J., Roberts H., and Schrezenmeir J. Ovariectomy induced bone loss in the minipig-An animal model for postmenopausal osteoporosis. Exp. Clin. Endocrinol. Diabetes 106 (1998) S9
55. Scholz-Ahrens K.E., Delling G., Jungblut P.W., Kallweit E., and Barth C.A. Effect of ovariectomy on bone histology and plasma parameters of bone metabolism in nulliparous and multiparous sows. Z. Ernährungswiss. 35 (1996) 13-21
56. Scholz-Ahrens K.E., Delling G., Stampa B., Barkmann R., Timm W., Schrezenmeir J., et al. Bone mineral density and trabecular structure in steroid-induced osteoporosis in minipigs. J. Bone Miner. Res. 15 (2000) S542
57. Schorlemmer S., Gohl C., Iwabu S., Ignatius A., Claes L., and Augat P. Glucocorticoid treatment of ovariectomized sheep affects mineral density, structure, and mechanical properties of cancellous bone. J. Bone Miner. Res. 18 (2003) 2010-2015
58. Schorlemmer S., Ignatius A., Claes L., and Augat P. Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 37 (2005) 491-496
59. Shen V., Birchman R., Liang X.G., Wu D.D., Lindsay R., and Dempster D.W. Prednisolone alone, or in combination with estrogen or dietary calcium deficiency or immobilization, inhibits bone formation but does not induce bone loss in mature rats. Bone 21 (1997) 345-351
60. Smith S.Y., Recker R.R., Hannan M., Muller R., and Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32 (2003) 45-55
61. Thomsen J.S., Ebbesen E.N., and Mosekilde L. A new method of comprehensive static histomorphometry applied on human lumbar vertebral cancellous bone. Bone 27 (2000) 129-138
62. Thomsen J.S., Ebbesen E.N., and Mosekilde L. Relationships between static histomorphometry and bone strength measurements in human iliac crest bone biopsies. Bone 22 (1998) 153-163
63. Tkocz-Kwiatkowska J., Kaczmarczyk-Sedlak I., and Folwarczna J. Effects of pamidronate on the development of changes in bone mechanical properties and bone structure caused by the administration of prednisolone in rats. Pol. J. Pharmacol. 50 (1998) 253-258
64. Trzenschik K., Lindenhayn K., and Buhler G. Inhibition of prednisolone osteopathy by diphosphonate (EHDP) in an animal experiment. Beitr. Orthop. Traumatol. 36 (1989) 81-91
65. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13 (2002) 777-787
66. Vedi S., Elkin S.L., and Compston J.E. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif. Tissue Int. 77 (2005) 79-83
67. Wallach S., Cohen S., Reid D.M., Hughes R.A., Hosking D.J., Laan R.F., et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67 (2000) 277-285
68. Wang Y., Ohtsuka-Isoya M., Shao P., Sakamoto S., and Shinoda H. Effects of methylprednisolone on bone formation and resorption in rats. Jpn. J. Pharmacol. 90 (2002) 236-246
69. Weinstein R.S. Glucocorticoid-induced osteoporosis. Rev. Endocr. Metab. Disord. 2 (2001) 65-73
70. Weinstein R.S., Chen J.R., Powers C.C., Stewart S.A., Landes R.D., Bellido T., et al. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J. Clin. Invest. 109 (2002) 1041-1048
71. Wimalawansa S.J., and Simmons D.J. Prevention of corticosteroid-induced bone loss with alendronate. Proc. Soc. Exp. Biol. Med. 217 (1998) 162-167
72. Zegels B., Eastell R., Russell R.G., Ethgen D., Roumagnac I., Collette J., et al. Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis. Bone 28 (2001) 108-112